- Trial Phase
- Phase 2b/3
- Time to Market
- At least 3-5 years if Phase 3 trials in obesity and breast cancer succeed; no approved product yet.
- Why 7/10
- The next hard dated catalyst is the Phase 2b PLATEAU interim analysis (enobosarm + semaglutide in obesity), expected in Q1 2027 (~6-9 months). Enobosarm is Veru's lead asset and drives most of the company's valuation. A positive readout could validate the combo for a massive obesity market; a negative readout would be devastating given Veru has zero commercial revenue.
Watch for the Phase 2b PLATEAU interim data in Q1 2027 — this is the key near-term binary. Monitor cash burn and ATM dilution pace; the July 2026 $21.8M ATM facility creates a persistent overhang. The Novo Nordisk supply agreement provides validation but can be terminated on 60 days' notice, so trial execution matters enormously.
Price Chart
Executive Summary
Enobosarm is Veru Inc.'s lead drug candidate — an oral SARM repurposed into two sizable markets: obesity (as an add-on to GLP-1 drugs to preserve muscle) and AR+ breast cancer. The obesity angle gained significant traction after positive Phase 2b QUALITY data (Jan 2025), FDA regulatory clarity on endpoints (Sep 2025), and a high-profile clinical supply agreement with Novo Nordisk (June 2026) that sent VERU shares up ~167%. However, Veru has zero commercial revenue, disclosed going-concern risk, and filed a $21.8M ATM equity facility (July 2026) that could dilute existing holders by ~43%. The next major catalyst is the Phase 2b PLATEAU interim readout in Q1 2027, making this a high-conviction but binary single-asset biotech story.
How It Works
Enobosarm is an oral "smart drug" called a SARM (Selective Androgen Receptor Modulator) that acts like targeted testosterone. It binds to androgen receptors in muscles and bone to build and preserve lean muscle mass without the masculinizing side effects of traditional steroids. In obesity, it's designed to be added to GLP-1 weight-loss drugs (like Wegovy/semaglutide) to prevent the muscle loss those drugs cause — turning weight loss into fat-only loss. In breast cancer, it activates the androgen receptor (which acts as a tumor suppressor in certain breast cancers) to slow cancer growth.
Trial Status
Phase 2b QUALITY obesity trial completed with positive topline data (January 2025). Phase 2b PLATEAU obesity trial (enobosarm + semaglutide) began enrolling March 2026 — interim analysis due Q1 2027, final data Q4 2027. Phase 3 ENABLAR-2 breast cancer trial (enobosarm + abemaciclib vs active control) is enrolling 186 patients in 2nd-line AR+ER+HER2- metastatic breast cancer. Phase 3 ARTEST (monotherapy in later-line breast cancer) was discontinued to prioritize ENABLAR-2. FDA Fast Track designation granted for breast cancer program.
The Two-Sided Case
Upcoming Catalysts
- Phase 2b PLATEAU (enobosarm + semaglutide) interim analysis — Q1 2027
- Phase 2b PLATEAU final topline data — Q4 2027
- Phase 3 ENABLAR-2 (enobosarm + abemaciclib in breast cancer) enrollment completion and potential interim data
- Potential partnership/licensing deal with Novo Nordisk if PLATEAU data is positive (ROFR clause)
- ATM equity sales pace — monitor for dilution frequency
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERU INC. 8-K VERU ·Originating report